GTHX - Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? | Benzinga
Shares of G1 Therapeutics Inc (NASDAQ:GTHX) are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered before chemotherapy (gemcitabine and carboplatin; GCb) for metastatic Metastatic Triple Negative Breast Cancer (TNBC).
In February, G1 Therapeutics shared an interim update on the Phase 3 PRESERVE 2 trial of trilaciclib.
The study did not demonstrate a statistically significant treatment effect in the Intent-to-Treat (ITT) population (n=187) with a hazard ratio (HR) of 0.91 (p=0.884).
The median overall survival (OS) in the trilaciclib plus GCb arm was 17.4 months compared ...